A phase 3 study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients 65 years with newly diagnosed multiple ...
Research on Global Markets has announced the addition of “Therapeutic Class Overview: Treating Refractory Hematological Malignancies “research report to their offering. The report provides an overview of the approved therapies for rrmm, ndmm, aml, mds, unmet need and limitations of the current soc for relapsed and refractory pts. For more information visit: http://www.researchonglobalmarkets.com/therapeutic-class-overview-treating-refractory-hematological-malignancies.html
The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts.
Treatment of Transplant Ineligible/Elderly MM Patients Myelomacenter.org run9001@med.cornell.edu Ruben Niesvizky Department of Medicine, Division of Hematology ...
Title: Challenging Cases in Multiple Myeloma Author: Research To Practice Description: www.ResearchToPractice.com/ONSMM2014 Last modified by: Silvana Izquierdo